

SUPPLEMENT

Figure S1. Proportions of patients achieving ASDAS responses among TNFi-naïve PsA patients with PA-PRS at Week 12 and Week 24 (A) and by HLA-B27 status at Week 12 (B) and Week 24 (C). Inactive disease = ASDAS score <1.3; major improvement = decrease in ASDAS ≥ 2.0 ; clinically-important improvement = decrease in ASDAS ≥ 1.1 . HLA-B27, human leukocyte antigen B27 allele; ASDAS, Ankylosing Spondylitis Disease Activity Score; PA-PRS, peripheral arthritis and physician-reported spondylitis; PsA, psoriatic arthritis; TNFi, tumor necrosis factor-inhibitor

